このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

先天性副腎過形成症の16歳以上の参加者におけるクロノコートと標準ヒドロコルチゾン補充療法の比較 (CONnECT)

2026年9月10日 更新者:Neurocrine UK Limited

先天性副腎過形成症の16歳以上の参加者における即時放出ヒドロコルチゾン補充療法と比較したクロノコートの無作為化、二重盲検、実薬対照、第3相研究

This study is a randomized, double-blind, active-controlled, phase III study of Chronocort® compared with immediate-release hydrocortisone replacement therapy in participants aged 16 years and over with Congenital Adrenal Hyperplasia.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

The study will compare the efficacy, safety and tolerability of twice daily Chronocort with twice daily immediate release hydrocortisone replacement therapy (IRHC) (Cortef®) in participants aged 16 years and over with known classic Congenital Adrenal Hyperplasia (CAH) due to 21 hydroxylase deficiency.

研究の種類

介入

入学 (実際)

55

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Los Angeles、California、アメリカ、90027
        • Diurnal Investigational Site in Los Angeles
      • Orange、California、アメリカ、92868
        • Diurnal Investigational Site in Orange
    • Florida
      • Jacksonville、Florida、アメリカ、32207
        • Diurnal Investigational Site in Jacksonville
    • Iowa
      • Iowa City、Iowa、アメリカ、52224
        • Diurnal Investigational Site in Iowa
    • Maryland
      • Bethesda、Maryland、アメリカ、20892-1932
        • Diurnal Investigational Site in Maryland
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • Diurnal Investigational Site in Michigan
    • Minnesota
      • Rochester、Minnesota、アメリカ、55901
        • Diurnal Investigational Site in Rochester
    • Nevada
      • Las Vegas、Nevada、アメリカ、89148
        • Diurnal Investigational Site in Nevada
    • Texas
      • Dallas、Texas、アメリカ、75235
        • Diurnal Investigational Site in Dallas
    • Washington
      • Seattle、Washington、アメリカ、98105
        • Diurnal Investigational Site in Seattle
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • Diurnal Investigational Site in Milwaukee
      • Bordeaux、フランス、33604
        • Diurnal Investigational Site in Pessac
      • Lyon、フランス、69677
        • Diurnal Investigational Site in Bron
      • Paris、フランス、75651
        • Diurnal Investigational Site in Paris
      • Toulouse、フランス、31059
        • Diurnal Investigational Site in Toulouse (Children's Hospital)
      • Toulouse、フランス、31059
        • Diurnal Investigational Site in Toulouse
    • Normandy
      • Caen、Normandy、フランス、14033
        • Diurnal Investigational Site in Caen
    • Kanagawa
      • Yokohama、Kanagawa、日本、241-0811
        • Diurnal Investigational Site in Asahi-ku
    • Tokyo
      • Bunkyō-Ku、Tokyo、日本、113-8519
        • Diurnal Investigational Site in Yushima
      • Setagaya-Ku、Tokyo、日本、157-8535
        • Diurnal Investigational Site in Okura
      • Shinjuku-Ku、Tokyo、日本、162-8655
        • Diurnal Investigational Site in Toyama

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

16年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or female participants must be aged 16 years or older at the time of signing the informed consent/assent.
  • In participants aged <18 years, height velocity must be less than 2 cm/year in the last year and puberty must be completed (Tanner stage V).
  • Participants with known classic CAH due to 21 hydroxylase deficiency diagnosed in childhood with documented (at any time) elevated 17-OHP and with or without elevated A4 and currently treated with hydrocortisone, prednisone, prednisolone or dexamethasone (or a combination of the aforementioned glucocorticoids) and on stable glucocorticoid therapy for a minimum of 3 months.
  • Participants who are receiving fludrocortisone must be on a documented stable dose for a minimum of 3 months prior to enrollment and must have stable renin levels at screening.
  • Female participants of childbearing potential and all male participants must agree to the use of an accepted method of contraception during the study.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and she is either not a woman of childbearing potential (WOCBP) or has a negative pregnancy test at entry into the study. Note: females presenting with oligomenorrhea or amenorrhea who are aged ≤55 years should be considered potentially fertile and therefore should undergo pregnancy testing like all other female participants.
  • Capable of giving signed informed consent/assent which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

  • Clinical or biochemical evidence of hepatic or renal disease e.g. creatinine >2 times the upper limit of normal (ULN) or elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >2 times the ULN).
  • History of bilateral adrenalectomy.
  • History of malignancy (other than basal cell carcinoma successfully treated >26 weeks prior to entry into the study).
  • Participants who have type 1 diabetes or receive regular insulin, have uncontrolled diabetes, or have a screening HbA1c greater than 8%.
  • Persistent signs of adrenal insufficiency or the participant does not tolerate treatment at the end of the 4-week run-in period.
  • Participants with any other significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study.
  • Participants on regular daily inhaled, topical, nasal or oral steroids for any indication other than CAH.
  • Co-morbid condition requiring daily administration of a medication or consumption of any material that interferes with the metabolism of glucocorticoids.
  • Participants who are receiving <10 mg hydrocortisone dose at screening or the hydrocortisone dose equivalent.
  • Participants anticipating regular prophylactic use of additional steroids e.g. for strenuous exercise.
  • Participation in another clinical study of an investigational or licensed drug or device within the 12 weeks prior to screening.
  • Inclusion in any natural history or translational research study that would require evaluation of androgen levels during the study period outside of this protocol's assessments.
  • Participants who have previously been exposed to Chronocort in any Diurnal study.
  • Participants who routinely work night shifts and so do not sleep during the usual night-time hours.
  • Participants, who in the opinion of the Investigator, will be unable to comply with the requirements of the protocol.
  • Participants with a known hypersensitivity to any of the components of the Chronocort capsules, the Cortef tablets, or the placebo capsules.
  • Participants with congenital galactosemia, malabsorption of glucose and galactose, or who are lactase deficient.
  • Participants with a body weight of 45 kg or less.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:Chronocort

Participants received Chronocort at a starting dose of 30 milligrams (mg), with dose adjustments down to 25, 20, or 15 mg based on adrenal insufficiency symptoms and androgen levels. Placebo was used for dose adjustment to maintain blinding.

Over-encapsulated hydrocortisone modified-release capsule for oral administration.

他の名前:
  • ヒドロコルチゾン修飾リリース

Matching placebo

アクティブコンパレータ:Cortef

Participants received Cortef at a starting dose of 30 mg, with dose adjustments down to 25, 20, or 15 mg based on adrenal insufficiency symptoms and androgen levels. Placebo was used for dose adjustment to maintain blinding.

Matching placebo

Over-encapsulated hydrocortisone immediate-release tablet for oral administration.

他の名前:
  • 即時放出ヒドロコルチゾン
  • IRHC

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Who Were Biochemical Responders at Week 28
時間枠:Week 28

Biochemical response was defined as a participant who a) was in biochemical control at the 08:00 assessment and b) was receiving a total daily dose of hydrocortisone of not more than 25 mg if the participant was in biochemical control at baseline or not more than 30 mg if the participant was not in biochemical control at baseline.

Biochemical control was defined as both a 17-OHP concentration equal to or below the upper limit for optimal control (1200 ng/dL [36.4 nmol/L]) and an A4 concentration equal to or below the upper limit of the reference range (150 ng/dL [5.2 nmol/L] for men and 200 ng/dL [7.0 nmol/L] for women).

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Week 28

二次結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants Who Were Dose Responders at Week 28
時間枠:Week 28

Dose response was defined as a participant who a) was receiving a total daily dose of hydrocortisone of not more than 25 mg and b) was in biochemical control at the 08:00 assessment.

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Week 28
Total Daily Dose of Hydrocortisone at Week 28
時間枠:Week 28

Least squares (LS) mean was assessed using mixed model repeated measures (MMRM).

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Week 28
Number of Participants in Biochemical Control
時間枠:Baseline and Week 28

Biochemical control was defined as both a 17-OHP concentration (assessed at 08:00) equal to or below the upper limit for optimal control (1200 ng/dL [36.4 nmol/L]) and an A4 concentration equal to or below the upper limit of the reference range (150 ng/dL [5.2 nmol/L] for men and 200 ng/dL [7.0 nmol/L] for women).

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline and Week 28
Change From Baseline in Mean of 08:00 and 13:00 17-OHP Levels at Week 28
時間枠:Baseline, Week 28

LS mean was assessed using analysis of covariance (ANCOVA). Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline in Mean of 08:00 and 13:00 A4 Levels at Week 28
時間枠:Baseline, Week 28

LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Number of Participants With Menstrual Regularity (Females of Childbearing Potential Only) at Week 28
時間枠:Week 28

Data are presented for the number of participants with more than monthly menstrual cycles, monthly menstrual cycles, and number of participants with oligomenorrhoea and amenorrhoea. Oligomenorrhoea was defined as fewer than 9 menstrual cycles per year or cycle length >35 days and amenorrhoea as absent menses for ≥ 3 months.

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Week 28
Change From Baseline in Luteinizing Hormone Levels (Males Only) at Week 28
時間枠:Baseline, Week 28

LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Percent Change From Baseline in Size of Testicular Adrenal Rest Tumors at Week 28 (Males Only)
時間枠:Week 28

Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Week 28
Change From Baseline in Hirsutism at Week 28 Using the Ferriman-Gallwey Score (Females Only) at Week 28
時間枠:Baseline, Week 28

Ferriman-Gallwey score is a method used to assess and quantify hirsutism in women. A total score < 8 is considered normal whereas a score of 8 to 15 indicates mild hirsutism. A score >15 indicates moderate or severe hirsutism. The Ferriman-Gallwey score ranged from 0 to 36. Higher score indicated more hirsutism. Change from baseline is reported (negative change from baseline indicated improvement).

LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline in Acne Using the Global Evaluation Acne (GEA) Scale (Females Only) at Week 28
時間枠:Baseline, Week 28

Acne severity was assessed according to GEA scale, which ranged from 0 (Clear. No lesions) to 5 (Very severe). Higher score indicated higher severity of acne. Change from baseline is reported (negative change from baseline indicated improvement).

LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline in Glycated Hemoglobin (HbA1c) Percent Levels at Week 28
時間枠:Baseline, Week 28

LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline in Waist Circumference at Week 28
時間枠:Baseline, Week 28

LS mean was assessed using ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline in Body Weight at Week 28
時間枠:Baseline, Week 28

LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28
Change From Baseline Quality of Life Using the Self-completed Medical Outcome Study 36-Item Short Form Health Survey (SF-36) Total Score for the Physical and Mental Components and the Sub-domain of Vitality at Week 28
時間枠:Baseline, Week 28

SF-36 evaluates aspects of functional health and well-being. The physical component has 4 sub-scales: physical function, role limitations due to physical problems, pain, and general health perception; and the mental component has 4 sub-scales: vitality, social function, role limitations due to emotional problems, and mental health. Total scores for the physical and mental component are presented as well as the sub-scale score for vitality. Scores were summarized and transformed into a range from 0 to 100; 0=worst, and 100=best outcome. Higher scores indicated better outcome. Change from baseline is reported (positive change from baseline indicated improvement).

LS mean was assessed by ANCOVA. Assessment of efficacy at Week 28 was a composite of each participant's on-treatment visit closest in time to 28 weeks post randomization.

Baseline, Week 28

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Principal Investigator、Immedica Pharma AB

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年5月24日

一次修了 (実際)

2024年2月2日

研究の完了 (実際)

2024年2月2日

試験登録日

最初に提出

2021年5月28日

QC基準を満たした最初の提出物

2021年9月30日

最初の投稿 (実際)

2021年10月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月10日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。